[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From The JAMA Web Sites
June 10, 1998

Analysis of Ritonavir for the Treatment of HIV Disease in Children

Author Affiliations

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;279(22):1785-1788. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-22-jac80008

In Reply.— By assessing outcomes in life-years rather than the limited end point of cost per abnormality, the cited study by Dr Schechter1 follows the format of a conventional cost-effectiveness analysis. Nevertheless, it does not address the use of PAPNET considered by Dr O'Leary and colleagues.2 The comparison with 100% manual rescreening, frequently discussed as a method that might improve the accuracy of Pap smear testing, is of substantial interest. The finding that PAPNET identified few additional abnormalities, and at very high cost, suggests that it is not cost-effective when an excellent laboratory uses it this way. A more elaborate analysis is not needed to draw this conclusion.

First Page Preview View Large
First page PDF preview
First page PDF preview